

PRODUCT SPECIFICATION SHEET

Bordet Gengou Agar Base (DM042)

Intended Use

Bordet Gengou Agar Base (DM042) is recommended for detection and isolation of *Bordetella pertussis* and *Bordetella parapertussis*.

Product Summary and Explanation

Bordetella pertussis, the etiologic agent of this disease, may be isolated from aspirated bronchial or nasopharyngeal secretions, perinasal swabs or, perhaps with greater difficulty due to the diversity of flora, from throat swabs.⁽¹⁾ *pertussis* is the causative agent of whooping cough and with the help of cough-plate technique. Bordet Gengou Agar Media were originally formulated by Bordet and Gengou⁽²⁾ for cultivation of *Bordetella* species. In 1934, Kendrick and Eldering⁽³⁾ modified the original media by replacing 50% human or rabbit blood with 15% sheep blood to make the medium more enriched for detection of *B. pertussis* by the virtue of its haemolytic reaction. Enrichment of the basal media with 25% human blood aids in the detection of *Mycobacterium* species from small sputum inocula and in Streptomycin sensitivity testing.⁽⁴⁾ The medium is highly nutritious thus supports luxuriant growth of *Bordetella* species and can also be used for mass cultivation of *B. pertussis* for vaccine production⁽³⁾ and for maintaining stock cultures.⁽²⁾

Principles of the Procedure

Bordet Gengou Agar Base contains potato infusion and peptic digest of animal tissue serve as carbon and nitrogen source while glycerol and blood enrichment provides additional nutrients to support the growth of *B. pertussis*. Sodium chloride maintains osmotic equilibrium. Defibrinated animal blood supplies additional nutrients and enables the detection of hemolytic reactions, which aid in the identification of *B. pertussis*. This medium can be made more selective for *Bordetella*, by using antibiotics like penicillin, methicillin, cephalixin of which, cephalixin was found to be superior. Cephalixin suppresses unwanted nasopharyngeal growth and significantly increases the isolation rate of *Bordetella* species. Cephalixin is used at a concentration of 40 mg/litre (MS003). Amphotericin B (10 µg/ml) can be added as an antifungal agent to the medium.

Formula / Liter

Ingredients	Gms / Liter
Potatoes, infusion from	125.00
Peptic digest of animal tissue	10.00
Sodium chloride	5.50
Agar	20.00
Final pH: 6.7 ± 0.2 at 25°C	
Formula may be adjusted and/or supplemented as required to meet performance specifications	

Precautions

1. For Laboratory Use only.
2. IRRITANT. Irritating to eyes, respiratory system, and skin.

Directions

1. Suspend 40 grams of the medium in one liter of distilled water containing 10 ml glycerol.
2. Heat if necessary, to dissolve the medium completely.
3. Autoclave at 121°C, 15 psi pressure, for 15 minutes / validated cycle.
4. Cool to 45-50°C and aseptically add 15 - 20% sterile, fresh defibrinated blood (sheep, rabbit, human or horse).
5. For selectivity aseptically add rehydrated contents of 2 vials of Bordetella Selective supplement (MS003).
6. Mix thoroughly, taking care to avoid incorporation of air bubbles and pour into sterile Petri plates.

Quality Control Specifications

Dehydrated Appearance	Cream to yellow homogeneous free flowing powder
Prepared Medium	Basal Medium: Light yellow coloured clear to slightly opalescent gel. After addition of glycerol and 15% v/v sterile defibrinated blood: Cherry red coloured opaque gel forms in Petri plates.

PRODUCT SPECIFICATION SHEET

Reaction of 4.00% Solution	pH : 6.7 ± 0.2 at 25°C
Gel Strength	Firm, comparable with 2.0% Agar gel

Expected Cultural Response: Cultural characteristics observed with added Glycerol and 15% v/v sterile defibrinated blood and Bordetella Selective Supplement (MS003), after an incubation at 35-37°C for 3-4 days.

Sr. No.	Organisms	Results to be achieved			
		Inoculum (CFU)	Growth	Recovery	Haemolysis
1.	<i>Bordetella bronchiseptica</i> ATCC 4617	50 -100	good-luxuriant	≥50 %	Gamma
2.	<i>Bordetella parapertussis</i> ATCC 15311	50 -100	good-luxuriant	≥50 %	Gamma
3.	<i>Bordetella pertussis</i> ATCC 8467	50 -100	good-luxuriant	≥50 %	Beta
4.	<i>Staphylococcus aureus</i> ATCC 25923	≥10 ³	Inhibited	0%	

The organisms listed are the minimum that should be used for quality control testing.

Test Procedure

1. For isolation of *B. pertussis* from specimens, use standard procedures.
2. Incubate the plates in a moist chamber at 35-37°C for 7 days and examine daily with or without dissecting microscope (oblique illumination) to detect the presence of *B. pertussis*.
3. Sometimes the accompanying mold colonies can mask the *B. pertussis* colonies. Use sterile scalpel or needle to remove the portion of the agar that contains spreading colonies of moulds.
4. *B. pertussis* colonies may not be visible without the aid of a microscope for 2-4 days. After 7 days of incubation plates may be discarded as negative.

Results

1. *Bordetella pertussis* produces small, smooth, raised, glistening colonies that resemble bisected pearls.
2. The colonies are usually surrounded by a zone of hemolysis; however, some strains of *B. pertussis* are not hemolytic.
3. Gram stains, biochemical tests and serological procedures should be performed to confirm findings.

Storage

On receipt, store plates at 2-8°C.

Expiration

Refer to the expiration date stamped on the pack. Prepared plates stored in their original sleeve wrapping at 2-8°C until just prior to use may be inoculated up to the expiration date and incubated for recommended incubation times.

Limitations of the Procedure

1. Some *Haemophilus* spp. will grow on *Bordetella* isolation media and cross-react with *B. pertussis* antisera. It may be prudent to rule out X and V factor dependence.
2. Consult appropriate texts for detailed information and recommended procedures.

Packaging

Product Name : Bordet Gengou Agar Base

Product Code : DMO42

Available Pack sizes : 100gm / 500gm

References

1. Loeffelholz and Sanden. 2007. In Murray, Baron, Jorgensen, Landry and Pfaller (ed.), Manual of clinical microbiology 9th ed. American Society for Microbiology, Washington, D.C.
2. Bordet and Gengou, 1906, Ann. Inst. Pasteur, 20:731.
3. Kendrick and Eldering, 1934, Am. J. Public Health, 24:309
4. Tarshis M. S. and Frisch A. W., 1951, Am. J. Clin. Pathol., 21:101.

PRODUCT SPECIFICATION SHEET



Further Information

For further information please contact your local MICROMASTER Representative.



MICROMASTER LABORATORIES PRIVATE LIMITED

DM042PSS, QAD/FR/024, Rev.00

Unit 38/39, Kalpataru Industrial Estate,
Off G.B. Road, Near 'R-Mall', Thane (W) - 400607. M.S. INDIA.
Ph: +91-9320126789/9833630009/9819991103
Email: sales@micromasterlab.com

Disclaimer :

All Products conform exclusively to the information contained in this and other related Micromaster Publications. Users must ensure that the product(s) is appropriate for their application, prior to use. The information published in this publication is based on research and development work carried out in our laboratory and is to the best of our knowledge true and accurate. Micromaster Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are intended for laboratory, diagnostic, research or further manufacturing use only and not for human or animal or therapeutic use, unless otherwise specified. Statements included herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

